<PAPER><mode2 name='PMC2874259' hasDoc='yes' version='597'></mode2><article xmlns:mml='http://www.w3.org/1998/Math/MathML' xmlns:xlink='http://www.w3.org/1999/xlink' article-type='research-article'><front><journal-meta><journal-id journal-id-type='nlm-ta'>Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &amp; Therapy</journal-title></journal-title-group><issn pub-type='epub'>1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type='pmcid'>2874259</article-id><article-id pub-id-type='publisher-id'>alzrt7</article-id><article-id pub-id-type='pmid'>19845950</article-id><article-id pub-id-type='doi'>10.1186/alzrt7</article-id><article-categories><subj-group subj-group-type='heading'><subject>Research</subject></subj-group></article-categories><title-group><article-title><s sid='1'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease</s></article-title></title-group><contrib-group><contrib contrib-type='author' corresp='yes' id='A1'><name><surname>Rountree</surname><given-names>Susan D</given-names></name><xref rid='I1' ref-type='aff'>1</xref><email>rountree@bcm.edu</email></contrib><contrib contrib-type='author' id='A2'><name><surname>Chan</surname><given-names>Wenyaw</given-names></name><xref rid='I2' ref-type='aff'>2</xref><email>Wenyaw.Chan@uth.tmc.edu</email></contrib><contrib contrib-type='author' id='A3'><name><surname>Pavlik</surname><given-names>Valory N</given-names></name><xref rid='I3' ref-type='aff'>3</xref><email>vpavlik@bcm.edu</email></contrib><contrib contrib-type='author' id='A4'><name><surname>Darby</surname><given-names>Eveleen J</given-names></name><xref rid='I1' ref-type='aff'>1</xref><email>darby@bcm.edu</email></contrib><contrib contrib-type='author' id='A5'><name><surname>Siddiqui</surname><given-names>Samina</given-names></name><xref rid='I4' ref-type='aff'>4</xref><email>saminas@yahoo.com</email></contrib><contrib contrib-type='author' id='A6'><name><surname>Doody</surname><given-names>Rachelle S</given-names></name><xref rid='I1' ref-type='aff'>1</xref><email>rdoody@bcm.edu</email></contrib></contrib-group><aff id='I1'><label>1</label>Department of Neurology, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, TX 77030, USA</aff><aff id='I2'><label>2</label>Division of Biostatistics, University of Texas School of Public Health, Division of Biostatistics, 1200 Herman Pressler, Suite 846, Houston, TX 77030, USA</aff><aff id='I3'><label>3</label>Department of Community and Family Medicine, Baylor College of Medicine, 3701 Kirby Drive, Houston, TX 77098, USA</aff><aff id='I4'><label>4</label>Department of Psychiatry, University of Texas Health Science Center, 2800 S MacGregor Way, Houston, TX 77021, USA</aff><pub-date pub-type='collection'><year>2009</year></pub-date><pub-date pub-type='epub'><day>21</day><month>10</month><year>2009</year></pub-date><volume>1</volume><issue>2</issue><fpage>7</fpage><lpage>7</lpage><history><date date-type='received'><day>27</day><month>4</month><year>2009</year></date><date date-type='rev-request'><day>18</day><month>6</month><year>2009</year></date><date date-type='rev-recd'><day>1</day><month>10</month><year>2009</year></date><date date-type='accepted'><day>21</day><month>10</month><year>2009</year></date></history><permissions><copyright-statement>Copyright ©2009 Rountree et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Rountree et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type='open-access' xlink:href='http://creativecommons.org/licenses/by/2.0'><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type='uri' xlink:href='http://creativecommons.org/licenses/by/2.0'>http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href='http://alzres.com/content/1/2/7'></self-uri><abstract><sec><title>Introduction</title><p><s sid='2'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1>There are no empiric data to support guidelines for duration of therapy with antidementia drugs.</s><s sid='3'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> This study examined whether persistent use of antidementia drugs slows clinical progression of Alzheimer disease (AD) assessed by repeated measures on serial tests of cognition and function.</s></p></sec><sec><title>Methods</title><p><s sid='4'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>Six hundred forty-one probable AD patients were followed prospectively at an academic center over 20 years.</s><s sid='5'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Cumulative drug exposure was expressed as a persistency index (PI) reflecting total years of drug use divided by total years of disease symptoms.</s><s sid='6'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Baseline and annual testing consisted of Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Baylor Profound Mental Status Examination (BPMSE), Clinical Dementia Rating-Sum of Boxes (CDR-SB), Physical Self-Maintenance Scale (PSMS), and Instrumental Activities of Daily Living (IADL).</s><s sid='7'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Annual change in slope of neuropsychological and functional tests as predicted by follow-up time, PI, and the interaction of these two variables was evaluated.</s></p></sec><sec><title>Results</title><p><s sid='8'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>PI was associated with significantly slower rates of decline (with, without adjustment for covariates) on MMSE (<italic>P </italic>&lt; 0.0001), PSMS (<italic>P </italic>&lt; 0.05), IADL (<italic>P </italic>&lt; 0.0001), and CDR-SB (<italic>P </italic>&lt; 0.001).</s><s sid='9'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> There was an insignificant trend (<italic>P </italic>= 0.053) for the PI to be associated with slower rate of decline on BPMSE.</s><s sid='10'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The association of PI with ADAS-Cog followed a quadratic trend (<italic>P </italic>&lt; 0.01).</s><s sid='11'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Analysis including both linear and quadratic terms suggests that PI slowed ADAS-Cog decline temporarily.</s><s sid='12'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The magnitude of the favorable effect of a rate change in PI was: MMSE 1 point per year, PSMS 0.4 points per year, IADL 1.4 points per year, and CDR-SB 0.6 points per year.</s><s sid='13'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The change in mean test scores is additive over the follow-up period (3 ± 1.94 years).</s></p></sec><sec><title>Conclusions</title><p><s sid='14'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>Persistent drug treatment had a positive impact on AD progression assessed by multiple cognitive, functional, and global outcome measures.</s><s sid='15'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> The magnitude of the treatment effect was clinically significant.</s><s sid='16'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Positive treatment effects were even found in those with advanced disease.</s></p></sec></abstract></article-meta></front><body><sec><title>Introduction</title><p><s sid='17'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Since 1993, five drugs have been marketed for the treatment of Alzheimer disease (AD).</s><s sid='18'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> These treatments are sometimes regarded as having only 'symptomatic' rather than 'disease-modifying' effects, although the utility of this distinction has been questioned [<xref rid='B1' ref-type='bibr'>1</xref>].</s><s sid='19'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The first cholinesterase inhibitor (ChEI) approved specifically to treat symptoms of AD was tacrine, but it is no longer used.</s><s sid='20'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Galantamine and rivastigmine (both approved for use in mild to moderate AD) and donepezil (approved for use in mild to severe AD) are reported to benefit cognition, function, and behavior in AD patients [<xref rid='B2' ref-type='bibr'>2</xref>-<xref rid='B9' ref-type='bibr'>9</xref>].</s><s sid='21'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Donepezil confers significant benefits in controlled studies lasting up to 1 year [<xref rid='B10' ref-type='bibr'>10</xref>,<xref rid='B11' ref-type='bibr'>11</xref>] in mild to moderate AD, and 6-month studies have reported that therapy is efficacious in severe and institutionalized patients [<xref rid='B12' ref-type='bibr'>12</xref>-<xref rid='B15' ref-type='bibr'>15</xref>].</s><s sid='22'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> One controlled 2-year study (AD2000) evaluated mild to moderate AD patients and found no significant differences between patients who took donepezil compared with placebo in institutionalization rates or progression to disability, but significant cognitive and functional effects were maintained in those who received active treatment, despite methodological flaws [<xref rid='B16' ref-type='bibr'>16</xref>,<xref rid='B17' ref-type='bibr'>17</xref>].</s></p><p><s sid='23'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Memantine modulates glutamate via <italic>N</italic>-methyl-<sc>D</sc>-aspartate (NMDA) receptor antagonism and was approved for treatment of moderate to severe AD based upon three pivotal trials.</s><s sid='24'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The first was a 12-week study of nursing home residents [<xref rid='B18' ref-type='bibr'>18</xref>].</s><s sid='25'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In a 7-month study, memantine monotherapy compared with placebo was beneficial [<xref rid='B19' ref-type='bibr'>19</xref>], and in a 6-month trial, combination therapy with memantine plus donepezil was superior to placebo plus donepezil [<xref rid='B20' ref-type='bibr'>20</xref>].</s><s sid='26'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A recently published 24-week trial that also evaluated moderate to severe AD patients suggested a weaker treatment effect with memantine monotherapy; treatment was not associated with significant overall cognitive or global changes in this trial, although there were apparent benefits at intermediate time points [<xref rid='B21' ref-type='bibr'>21</xref>].</s><s sid='27'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Observations from the pivotal trials indicate that early initiation of treatment is associated with greater long-term benefit and that withdrawal and re-initiation of treatment is detrimental [<xref rid='B22' ref-type='bibr'>22</xref>].</s></p><p><s sid='28'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Observational studies suggest that these drugs may benefit cognition for a year [<xref rid='B23' ref-type='bibr'>23</xref>] or slow time to dementia-related nursing home placement [<xref rid='B24' ref-type='bibr'>24</xref>,<xref rid='B25' ref-type='bibr'>25</xref>].</s><s sid='29'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Two recent studies have evaluated the long-term use of a ChEI alone compared with a drug regimen including both a ChEI and memantine.</s><s sid='30'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In one study, AD patients followed for an average of 30 months taking a ChEI plus memantine had slower cognitive and functional decline compared with those taking only a ChEI or those receiving no treatment [<xref rid='B26' ref-type='bibr'>26</xref>].</s><s sid='31'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In another study, AD patients followed for an average of 5 years had significant delay until nursing home admission if they had used a ChEI, and the effect was significantly augmented if they had used a ChEI plus memantine [<xref rid='B27' ref-type='bibr'>27</xref>].</s><s sid='32'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The ethical dilemma of prolonged exposure to placebo limits longer-duration randomized trials, so only a practice-based population can provide longer observation [<xref rid='B28' ref-type='bibr'>28</xref>].</s></p><p><s sid='33'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1>No studies have evaluated the optimal duration of therapy or whether greater persistency of antidementia drug therapy affects patient outcomes.</s><s sid='34'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> We hypothesized that greater cumulative exposure to the ChEIs or memantine or both would be associated with slower rates of decline on cognitive and functional measures in AD patients over the long term.</s><s sid='35'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> We assessed the impact of persistent treatment from the onset of symptoms on key measures of disease progression.</s><s sid='36'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> This study was made possible by the longitudinal database at the Baylor College of Medicine (BCM), in which medication exposure throughout the disease course is quantified, serial measurements of cognition and function are collected annually, and the majority of patients are followed from diagnosis to death.</s></p></sec><sec sec-type='materials|methods'><title>Materials and methods</title><sec><title>Subjects</title><p><s sid='37'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>All members of this cohort agreed to participate in a database approved by the institutional review board at BCM and met criteria for the diagnosis of probable AD as determined by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association [<xref rid='B29' ref-type='bibr'>29</xref>].</s><s sid='38'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> All probable AD patients with at least one complete comprehensive annual follow-up evaluation were eligible.</s><s sid='39'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> All patients underwent an evaluation by a neurologist and completed a standardized dementia workup that has been in continuous use since 1989 [<xref rid='B30' ref-type='bibr'>30</xref>].</s><s sid='40'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> A detailed history and interview with the patient and an informant, neurological and physical examinations, a neuroimaging study of the brain, neuropsychological testing, and screening laboratory studies were performed at the initial visit.</s><s sid='41'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The duration of illness is estimated by the physician by a standardized procedure reported to the nearest half-year [<xref rid='B31' ref-type='bibr'>31</xref>].</s><s sid='42'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> We use a standardized method to estimate duration of illness in AD patients.</s><s sid='43'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> There is a set of questions for generating an estimate regarding the date of first symptoms to the nearest half-year.</s><s sid='44'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Physicians revise this estimate in conjunction with medical record review and patient/informant interviews and by testing the estimate by recall of life events.</s><s sid='45'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Inter-rater reliability for the estimate has been reported to be 0.95.</s><s sid='46'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The initial battery of neuropsychological tests is repeated along with neurological and physical exams annually.</s><s sid='47'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Each patient's diagnosis is reviewed at a consensus conference held weekly at BCM following the baseline and annual testing.</s><s sid='48'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Vital status was obtained from the National Death Index every 6 months, and the last inquiry was made in March 2006 with a censoring date for the analysis on 31 December 2005.</s><s sid='49'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> At censoring, 54% of the cohort had died and 46% were alive.</s></p></sec><sec><title>Persistency index</title><p><s sid='50'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Persistent drug exposure was calculated by a persistency index (PI): total years of drug use divided by the total years of disease symptoms.</s><s sid='51'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> This index includes the time period before the new patient visit.</s><s sid='52'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The number of years of disease symptoms was determined by the physician's estimate at the initial visit and extended to the last outcome assessment date.</s></p></sec><sec><title>Exposure</title><p><s sid='53'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1>Exposure to the antidementia drugs was ascertained for each subject.</s><s sid='54'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Early drug exposure information (prior to the initial visit) was recorded by the physician at the first clinic visit by history obtained from the patient and caregiver along with a review of medical records.</s><s sid='55'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The clinician seeing the patient completed a drug exposure form at each clinic visit and recorded all start dates and end dates, if applicable, for use of ChEIs, memantine, and other antidementia drugs.</s><s sid='56'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Lapses in treatment or switching from one drug to another was also noted and recorded by the treating physician.</s><s sid='57'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The dates of drug exposure were concurrently entered in the electronic database so the cumulative time on medication could be determined.</s><s sid='58'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We used chart review to complete drug exposure forms for the subjects who had been seen prior to the implementation of the drug exposure form in 2002.</s><s sid='59'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We also reconciled any exposure that occurred by virtue of participation in a clinical research trial by reviewing treatment assignments and study records.</s><s sid='60'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Exposure to antidementia drugs was calculated in months of use.</s><s sid='61'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> No attempt was made to quantify the dose or to distinguish between outcomes on monotherapy with a ChEI or combination therapy with a ChEI and glutamate modulator.</s><s sid='62'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Historically, ChEIs were widely available after the introduction of tacrine in 1993, donepezil in 1996, rivastigmine in 2000, and galantamine in 2001.</s><s sid='63'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Combination therapy or multiple-drug use did not often occur until memantine was approved in October 2003.</s></p></sec><sec><title>Neuropsychological testing</title><p><s sid='64'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Serial measures of cognition pertinent to this analysis included the Mini-Mental State Examination (MMSE) [<xref rid='B32' ref-type='bibr'>32</xref>], a widely used dementia severity test with scores that range from 0 to 30 points.</s><s sid='65'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Higher scores reflect better performance.</s><s sid='66'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The Baylor Profound Mental Status Examination (BPMSE) [<xref rid='B33' ref-type='bibr'>33</xref>] was administered when the MMSE score was 10 or below.</s><s sid='67'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The BPMSE is sensitive to longitudinal change and evaluates decline in advanced-stage AD when performance reaches lowest levels on conventional measures.</s><s sid='68'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> It is modeled after the MMSE and consists of 25 patient-derived cognitive questions that assess orientation, language, attention, and motor functioning.</s><s sid='69'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Higher scores reflect better cognitive performance.</s><s sid='70'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) [<xref rid='B34' ref-type='bibr'>34</xref>] measures cognitive domains often impaired in AD, including memory, language, and praxis.</s><s sid='71'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The error score ranges from 0 to 70, and higher scores reflect greater cognitive impairment.</s><s sid='72'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The ADAS-Cog is thought to be more sensitive to smaller changes in cognitive function than the MMSE but is less widely used clinically.</s><s sid='73'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The global measure was the Clinical Dementia Rating-Sum of Boxes (CDR-SB) [<xref rid='B35' ref-type='bibr'>35</xref>-<xref rid='B37' ref-type='bibr'>37</xref>].</s><s sid='74'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The score is derived from a patient interview in conjunction with an interview of a collateral source.</s><s sid='75'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The CDR-SB is obtained by summing the rating in each of six cognitive domains or 'boxes': personal care, affairs in the community and at home, judgment, orientation, and memory.</s><s sid='76'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Higher scores (range 0 to 18) reflect greater global impairment.</s><s sid='77'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> To evaluate activities of daily living, we used functional rating scales: the Physical Self-Maintenance Scale (PSMS) and Instrumental Activities of Daily Living (IADL) scale [<xref rid='B38' ref-type='bibr'>38</xref>].</s><s sid='78'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> These tests require input from the caregiver or an informant to evaluate the basic activities involving physical self-care (PSMS) and performance of complex daily functional activities essential to independence (IADL).</s><s sid='79'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The PSMS evaluates six aspects of self-care: toilet, feeding, dressing, grooming, ambulation, and bathing.</s><s sid='80'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Each item is scored from 1 to 5, and the maximum score is 30.</s><s sid='81'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The IADL evaluates eight complex tasks, including the use of the telephone, ability to shop, and mode of transportation.</s><s sid='82'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A score of zero can be assigned for five of the items if the patient did not perform the activity in question prior to the onset of illness: food preparation, housekeeping, laundry, ability to handle finances, and responsibility for medications.</s><s sid='83'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The maximum score is 31.</s><s sid='84'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Higher scores on the PSMS and IADL indicate greater functional impairment.</s></p></sec><sec><title>Pre-progression rate</title><p><s sid='85'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>AD patients progress at different rates but little is known about factors that explain the variance.</s><s sid='86'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The pre-progression rate is an easily calculable index of early disease progression and has prognostic value in classifying patients as rapid, intermediate, or slow progressors.</s><s sid='87'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> It is calculated as (the MMSE score [expected 30] - MMSE score [initial])/physician's estimate of symptom duration (in years).</s><s sid='88'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The pre-progression rate is significant in determining time to clinically meaningful decline during longitudinal follow-up [<xref rid='B39' ref-type='bibr'>39</xref>,<xref rid='B40' ref-type='bibr'>40</xref>].</s><s sid='89'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> It was therefore an important covariate in the current analysis.</s></p></sec><sec><title>Covariates</title><p><s sid='90'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Age, gender, years of education, baseline severity of dementia (mild, moderate, or severe based on MMSE score), pre-progression rate, and an indicator variable reflecting whether a patient had started on antidementia therapy before their initial visit to the Alzheimer's Disease and Memory Disorders Center.</s><s sid='91'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The use of drug prior to the initial visit (early exposure index) was used to control for the effects of early treatment or the propensity to take medication or both.</s></p></sec><sec><title>Statistical analysis</title><p><s sid='92'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Descriptive statistics (that is, frequencies for categorical variables and means and standard deviations for continuous variables) for the following variables were determined for the group as a whole at baseline: gender, age, education, physician's estimate of symptom duration, early exposure index, MMSE, ADAS-Cog, PSMS, IADL, CDR-SB, and BPMSE.</s><s sid='93'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Repeated measurement (random effects) linear modeling was used to examine the impact of cumulative antidementia drug exposure (PI) on change in the slope or rate of decline for the neuropsychological tests.</s><s sid='94'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Since this study focused on cohort average effect, no specific random effect was added to the model on any particular covariate, except assuming the existence of correlation between two outcome observations of the same subject.</s><s sid='95'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The correlation between two observations of any neuropsychological variable was assumed to follow an autoregressive correlation model of order 1.</s><s sid='96'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> This model takes into consideration that the correlation of two observations for each outcome variable is inversely proportional to the time interval between these two measurements.</s><s sid='97'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The primary model included time from the first visit, PI, interaction of these two terms, and pre-progression rate at the initial visit.</s><s sid='98'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Adjustments were then made for age, gender, years of education, baseline severity of dementia (mild, moderate, or severe based on MMSE score), and early exposure index (categorical).</s><s sid='99'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The outcome data for each measure were evaluated for significance of the quadratic relationship, including both linear and quadratic trend change.</s><s sid='100'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The regression coefficient associated with the variable PI indicated the amount of change in cognitive/functional performance or change in mean test score associated with a unit change in the PI at baseline.</s><s sid='101'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The regression coefficient associated with the interaction of time from the first visit and PI (PI × time) indicated the rate of decline on neuropsychological tests or change in the slope associated with a unit change in the PI.</s></p></sec></sec><sec><title>Results</title><p><s sid='102'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>There were 672 eligible subjects.</s><s sid='103'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Among them, 31 did not have either PI or complete neuropsychological measurements at any time point and were excluded from the analysis.</s><s sid='104'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> We compared the sample of included patients (n = 641) and those subjects who were missing an important covariate (n = 31) and found no significant differences in gender, years of education, age, or number of clinic visits (analysis not reported).</s><s sid='105'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The excluded subjects had a significantly longer duration of symptoms and higher early exposure index at the new patient visit (<italic>P </italic>&lt; 0.01).</s><s sid='106'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Baseline demographic characteristics were age, gender, years of education and symptom duration, average follow-up time, number of annual visits, and the early exposure index (Table <xref rid='T1' ref-type='table'>1</xref>) and the baseline scores on the ADAS-Cog, MMSE, BPMSE, IADL, PSMS, and CDR-SB (Table <xref rid='T2' ref-type='table'>2</xref>).</s><s sid='107'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> A frequency analysis of drug exposures in the 641 patients indicated that 43% of the group had been exposed to drug before the initial visit and 43% began treatment within 2 years following the new patient visit.</s><s sid='108'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> The percentage of individuals who were using medication at baseline increased with the duration of symptoms.</s><s sid='109'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Over the entire period of follow-up, 12% never used medication (Table <xref rid='T3' ref-type='table'>3</xref>).</s><s sid='110'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In the longitudinal data including all visits, there were equal proportions on a ChEI alone (n = 1,623) or combination therapy of a ChEI and memantine (n = 1,627) and few taking only memantine (n = 169).</s></p><table-wrap id='T1' position='float'><label>Table 1</label><caption><p>Baseline characteristics of patients with Alzheimer disease</p></caption><table rules='groups' frame='hsides'><thead><tr><th align='left'>Variable (n = 641)</th><th align='center'>Value</th><th align='center'>Range</th></tr></thead><tbody><tr><td align='left'>Age, years</td><td align='center'>73 (8.50)</td><td align='center'>43-93</td></tr><tr><td colspan='3'><hr></hr></td></tr><tr><td align='left'>Female</td><td align='center'>68%</td><td></td></tr><tr><td colspan='3'><hr></hr></td></tr><tr><td align='left'>Education, years</td><td align='center'>14 (3.56)</td><td align='center'>0-29</td></tr><tr><td colspan='3'><hr></hr></td></tr><tr><td align='left'>Early exposure index, years</td><td align='center'>0.5 (0.27)</td><td align='center'>0-1</td></tr><tr><td colspan='3'><hr></hr></td></tr><tr><td align='left'>Duration of symptoms before initial visit, years</td><td align='center'>3.7 (2.29)</td><td align='center'>0.5-13</td></tr><tr><td colspan='3'><hr></hr></td></tr><tr><td align='left'>Follow-up time, years</td><td align='center'>3.0 (1.94)</td><td align='center'>0.8-13.4</td></tr><tr><td colspan='3'><hr></hr></td></tr><tr><td align='left'>Total number of visits</td><td align='center'>3.4 (1.64)</td><td align='center'>2-11</td></tr></tbody></table><table-wrap-foot><p>For all continuous variables, values are presented as mean (standard deviation).</p></table-wrap-foot></table-wrap><table-wrap id='T2' position='float'><label>Table 2</label><caption><p>Baseline neuropsychological test scores</p></caption><table rules='groups' frame='hsides'><thead><tr><th align='left'>Variable (n = 641)</th><th align='center'>Average score</th><th align='center'>Range</th></tr></thead><tbody><tr><td align='left'>MMSE</td><td align='center'>19.5 (6.64)</td><td align='center'>0-30</td></tr><tr><td colspan='3'><hr></hr></td></tr><tr><td align='left'>ADAS-Cog</td><td align='center'>24.3 (12.43)</td><td align='center'>1-68</td></tr><tr><td colspan='3'><hr></hr></td></tr><tr><td align='left'>BPMSE</td><td align='center'>19.6 (5.96)</td><td align='center'>0-25</td></tr><tr><td colspan='3'><hr></hr></td></tr><tr><td align='left'>CDR-SB</td><td align='center'>6.7 (4.02)</td><td align='center'>0.5-18</td></tr><tr><td colspan='3'><hr></hr></td></tr><tr><td align='left'>IADL</td><td align='center'>15.5 (6.50)</td><td align='center'>2-31</td></tr><tr><td colspan='3'><hr></hr></td></tr><tr><td align='left'>PSMS</td><td align='center'>7.9 (3.05)</td><td align='center'>6-25</td></tr></tbody></table><table-wrap-foot><p>For all continuous variables, values are presented as mean (standard deviation). ADAS-Cog, Alzheimer's Disease Assessment Scale-Cognitive Subscale; BPMSE, Baylor Profound Mental Status Examination; CDR-SB, Clinical Dementia Rating-Sum of Boxes; IADL, Instrumental Activities of Daily Living; MMSE, Mini-Mental State Examination; PSMS, Physical Self-Maintenance Scale.</p></table-wrap-foot></table-wrap><table-wrap id='T3' position='float'><label>Table 3</label><caption><p>Drug exposure and duration of illness</p></caption><table rules='groups' frame='hsides'><thead><tr><th></th><th colspan='5' align='center'>Treatment initiated</th></tr></thead><tbody><tr><td align='left'><bold>Duration of symptoms at the NPV</bold></td><td align='center'><bold>Before NPV</bold></td><td align='center'><bold>1-2 years after NPV</bold></td><td align='center'><bold>3 years after NPV</bold></td><td align='center'><bold>Never treated</bold></td><td align='center'><bold>Total</bold></td></tr><tr><td colspan='6'><hr></hr></td></tr><tr><td align='left'>&lt;2 years</td><td align='center'>37 (5.8)</td><td align='center'>49 (7.6)</td><td align='center'>5 (0.8)</td><td align='center'>18 (2.8)</td><td align='center'>109 (17.0)</td></tr><tr><td colspan='6'><hr></hr></td></tr><tr><td align='left'>2-3 years</td><td align='center'>98 (15.3)</td><td align='center'>112 (17.5)</td><td align='center'>10 (1.6)</td><td align='center'>33 (5.1)</td><td align='center'>253 (39.5)</td></tr><tr><td colspan='6'><hr></hr></td></tr><tr><td align='left'>4-5 years</td><td align='center'>79 (12.3)</td><td align='center'>80 (12.5)</td><td align='center'>2 (0.3)</td><td align='center'>13 (2.0)</td><td align='center'>174 (27.1)</td></tr><tr><td colspan='6'><hr></hr></td></tr><tr><td align='left'>≥6 years</td><td align='center'>59 (9.2)</td><td align='center'>34 (5.3)</td><td align='center'>1 (0.2)</td><td align='center'>11 (1.7)</td><td align='center'>105 (16.4)</td></tr><tr><td colspan='6'><hr></hr></td></tr><tr><td align='left'>Total</td><td align='center'>273 (42.6)</td><td align='center'>275 (42.9)</td><td align='center'>18 (2.8)</td><td align='center'>75 (11.7)</td><td align='center'>641 (100.0)</td></tr></tbody></table><table-wrap-foot><p>Values are presented as number (percentage). NPV, new patient visit.</p></table-wrap-foot></table-wrap><p><s sid='111'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1>In a linear model, greater antidementia drug use was significantly associated with a slower rate of decline over time on the MMSE (<italic>P </italic>&lt; 0.0001), ADAS-Cog (<italic>P </italic>&lt; 0.01), PSMS (<italic>P </italic>&lt; 0.05), IADL (<italic>P </italic>&lt; 0.0001), and CDR-SB (<italic>P </italic>&lt; 0.001).</s><s sid='112'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> There was a trend (<italic>P </italic>= 0.053) indicating that greater antidementia drug was associated with a slower rate of decline on BPMSE (Table <xref rid='T4' ref-type='table'>4</xref>, PI × time).</s><s sid='113'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Assumptions of linear change were valid for all of the rating scales except the ADAS-Cog.</s><s sid='114'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Including both linear and quadratic terms in the model for ADAS-Cog change, we found that greater antidementia drug use was associated with a slower rate of decline on the ADAS-Cog for the first 3.3 years and that afterwards the positive treatment effect diminished.</s></p><table-wrap id='T4' position='float'><label>Table 4</label><caption><p>Relationship between persistency index and outcome measures (mixed effects regression analysis)</p></caption><table rules='groups' frame='hsides'><thead><tr><th align='left'><bold>Outcome(s) with adjustment</bold><sup>a</sup></th><th align='center'>Intercept</th><th align='center'>Time, years</th><th align='center'>Persistency index</th><th align='center'>Persistency index × time</th></tr></thead><tbody><tr><td></td><td colspan='4' align='center'><bold>Beta coefficient<sup>b </sup>(standard error)</bold></td></tr><tr><td colspan='5'><hr></hr></td></tr><tr><td align='left'>MMSE</td><td align='center'>3.89 (2.001)</td><td align='center'>-2.58 (0.13)<sup>c</sup></td><td align='center'>-1.09 (0.77)</td><td align='center'>1.02 (0.23)<sup>c</sup></td></tr><tr><td colspan='5'><hr></hr></td></tr><tr><td align='left'>ADAS-Cog<sup>d</sup></td><td align='center'>55.45 (5.65)<sup>c</sup></td><td align='center'>3.68 (0.66)<sup>c</sup></td><td align='center'>-3.75 (2.09)</td><td align='center'>2.74 (1.32)<sup>e</sup></td></tr><tr><td colspan='5'><hr></hr></td></tr><tr><td align='left'>BPMSE</td><td align='center'>10.46 (3.47)<sup>e</sup></td><td align='center'>-2.55 (0.25)<sup>c</sup></td><td align='center'>-1.76 (1.90)</td><td align='center'>1.00 (0.52)</td></tr><tr><td colspan='5'><hr></hr></td></tr><tr><td align='left'>PSMS</td><td align='center'>10.03 (1.85)<sup>c</sup></td><td align='center'>1.68 (0.12)<sup>c</sup></td><td align='center'>-0.09 (0.66)</td><td align='center'>-0.43 (0.21)<sup>f</sup></td></tr><tr><td colspan='5'><hr></hr></td></tr><tr><td align='left'>IADL</td><td align='center'>18.63 (2.54)<sup>c</sup></td><td align='center'>2.36 (0.17)<sup>c</sup></td><td align='center'>4.19 (0.91)<sup>c</sup></td><td align='center'>-1.42 (0.29)<sup>c</sup></td></tr><tr><td colspan='5'><hr></hr></td></tr><tr><td align='left'>CDR-SB</td><td align='center'>11.43 (1.43)<sup>c</sup></td><td align='center'>1.67 (0.09)<sup>c</sup></td><td align='center'>1.42 (0.54)<sup>e</sup></td><td align='center'>-0.61 (0.17)<sup>g</sup></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Adjustment made for early exposure index, gender, education, age, pre-progression rate, and the severity of disease at baseline. <sup>b</sup>Mean change in score associated with each variable. <sup>c</sup><italic>P </italic>&lt; 0.0001. <sup>d</sup>When the linear trend and quadratic trend change were included in the model the coefficients (standard errors) for time-squared and time-squared by persistency index interaction are 0.19 (0.14) and -0.83 (0.26)<sup>e</sup>, respectively. <sup>e</sup><italic>P </italic>&lt; 0.01; <sup>f</sup><italic>P </italic>&lt; 0.05; <sup>g</sup><italic>P </italic>&lt; 0.001; otherwise, <italic>P </italic>= not significant, based on type 3 F test. ADAS-Cog, Alzheimer's Disease Assessment Scale-Cognitive Subscale; BPMSE, Baylor Profound Mental Status Examination; CDR-SB, Clinical Dementia Rating-Sum of Boxes; IADL, Instrumental Activities of Daily Living; MMSE, Mini-Mental State Examination; PSMS, Physical Self-Maintenance Scale.</p></table-wrap-foot></table-wrap><p><s sid='115'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The magnitude of the treatment effect was clinically relevant.</s><s sid='116'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The rate of change in mean test scores indicated that maximally treated compared with untreated patients would have less decline on the rating scales: 1 point per year on the MMSE, 0.4 points per year on the PSMS, 1.4 points per year on the IADL, and 0.6 points per year on the CDR-SB.</s><s sid='117'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> These treatment effects are additive over the entire period of observation.</s><s sid='118'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> After 5 years, maximally treated patients would retain 4 more points on the MMSE, 2 fewer points on the PSMS, 3 fewer points on the IADL, and 1.6 fewer points on the CDR-SB.</s><s sid='119'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The benefits are also reflected in the ADAS-Cog, but properties of this test suggest that after about 3 years the persistent treatment effect is no longer detectable.</s><s sid='120'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Overall, there appears to be incremental benefit associated with greater cumulative antidementia drug use.</s></p></sec><sec><title>Discussion</title><p><s sid='121'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>Patients who received more persistent exposure to the antidementia drugs over the course of their illness had a significantly slower rate of decline on key measures of cognition, global functioning, and basic activities of daily living.</s><s sid='122'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> These effects are cumulative over time.</s><s sid='123'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Our results are consistent with a recent 3-year prospective study that compared outpatients taking ChEIs with untreated historical controls and that found that treatment was associated with fewer declines on a global dementia rating scale (Clinician Interview Based Impression of Change) and with significantly improved cognition as assessed by the MMSE and ADAS-Cog [<xref rid='B41' ref-type='bibr'>41</xref>].</s><s sid='124'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Our study indicates that persistent treatment is associated with positive benefit over the entire course of the disease and is reflected in both cognitive and functional outcomes.</s></p><p><s sid='125'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>One shortcoming of this study is that drug exposure was not assigned randomly, so we could not explore potential differences in combinations of antidementia drugs.</s><s sid='126'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In addition, we did not have data on indications for treatment or MMSE scores before the patients were first evaluated at our center.</s><s sid='127'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The PI was constant (not time-dependent) and did not reflect the outcome for each patient at each time point.</s><s sid='128'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> PI as determined by the last observation was related in the analysis to earlier cognitive assessments.</s><s sid='129'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> However, our objective was to evaluate the cumulative benefit of therapy over the life span rather than short-term treatment effects.</s><s sid='130'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Uncontrolled variables related to disease severity or duration of symptoms or both, perceived benefits from treatment, or other unmeasured factors (including behavioral symptoms or medical comorbidity) may have influenced the observed relationship between persistency of drug use and outcomes.</s><s sid='131'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The fact that our study included both treated and untreated individuals, even in subcohorts examined by duration of symptoms and total follow-up time (Table <xref rid='T3' ref-type='table'>3</xref>), contributes to the validity of the findings.</s></p><p><s sid='132'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>It is possible that individuals who take the antidementia drugs consistently have naturally slow disease progression and that their milder disease course could be falsely attributed to drug treatment.</s><s sid='133'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We cannot rule out the possibility that selection factors related to disease severity or perceived benefits from treatment influenced the observed relationship between persistency of drug use and outcomes.</s><s sid='134'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We adjusted the analysis by calculating an early exposure index to correct for the propensity to take medication, but this adjustment may not fully control the confounding factor.</s><s sid='135'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> In an exploratory model that adjusted for the duration of symptoms rather than the pre-progression rate, we found that taking drug before the first visit was associated with worse cognitive and functional tests yet that cumulative drug use remained beneficial.</s><s sid='136'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> This suggests that more rapid progressors, rather than slow progressors, are more likely to have been started on drug prior to the initial visit.</s></p></sec><sec><title>Conclusions</title><p><s sid='137'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>This study suggests that the more persistent that patients are and the longer that they persist with treatment the better they will perform on cognitive, global, and functional outcomes.</s><s sid='138'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> The modest findings of one long-duration trial (AD2000) that included regular washouts of treatment might be explained, in part, by lack of treatment persistence [<xref rid='B16' ref-type='bibr'>16</xref>].</s><s sid='139'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> The impact of AD therapy should be judged by the cumulative benefit over the duration of the disease.</s><s sid='140'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Our findings also suggest that antidementia drugs may benefit patients even when given in advanced or profound stages of AD.</s></p></sec><sec><title>Abbreviations</title><p>AD: Alzheimer disease; ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale; BCM: Baylor College of Medicine; BPMSE: Baylor Profound Mental Status Examination; CDR-SB: Clinical Dementia Rating-Sum of Boxes; ChEI: cholinesterase inhibitor; IADL: Instrumental Activities of Daily Living; MMSE: Mini-Mental State Examination; PI: persistency index; PSMS: Physical Self-Maintenance Scale.</p></sec><sec><title>Competing interests</title><p>SDR has been the principal investigator of a grant award to her institution from the Forest Research Institute (Jersey City, NJ, USA), is the principal investigator of clinical trial grants from Medivation (San Francisco, CA, USA) and Sonexa Therapeutics (San Diego, CA, USA), and has been a consultant to Eisai (Woodcliff Lake, NJ, USA), Forest Laboratories, Inc. (New York, NY, USA), Novartis (Basel, Switzerland), and Pfizer Inc (New York, NY, USA). RSD has been the principal investigator for clinical trials granted to her institution from Eisai, is the principal investigator of clinical trial grants from Pfizer Inc, Elan Corporation (Dublin, Ireland), and Wyeth (Madison, NJ, USA), and has been a consultant to Eisai, Forest Research Institute, Novartis, and Pfizer Inc. The other authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>SDR conceptualized and designed the study, drafted the manuscript, and has given final approval of the version to be published. WC, VNP, and RSD made substantial contributions to the conception and design of the study and to the analysis and interpretation of data. EJD and SS assisted with the acquisition of data and the analysis. All authors read and approved the final manuscript.</p></sec></body><back><sec><title>Acknowledgements</title><p>This study was supported by the Cynthia Woods Mitchell Endowed Research Fund, a Zenith Award from the Alzheimer's Association (RSD), and an unrestricted educational grant from the Forest Research Institute (SDR). The funding sources had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. The corresponding author had full access to all of the data in the study and had final responsibility for the decision to submit the paper for publication.</p></sec><ref-list><ref id='B1'><mixed-citation publication-type='journal'><name><surname>Doody</surname><given-names>R</given-names></name><article-title>We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer's disease drug development</article-title><source>Alzheimers Dement</source><year>2008</year><volume>4</volume><fpage>S21</fpage><lpage>25</lpage><pub-id pub-id-type='doi'>10.1016/j.jalz.2007.10.010</pub-id><pub-id pub-id-type='pmid'>18631995</pub-id></mixed-citation></ref><ref id='B2'><mixed-citation publication-type='journal'><name><surname>Rogers</surname><given-names>S</given-names></name><name><surname>Doody</surname><given-names>R</given-names></name><name><surname>Mohs</surname><given-names>R</given-names></name><name><surname>Friedhoff</surname><given-names>L</given-names></name><article-title>Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil study group</article-title><source>Arch Intern Med</source><year>1998</year><volume>158</volume><fpage>1021</fpage><lpage>1031</lpage><pub-id pub-id-type='doi'>10.1001/archinte.158.9.1021</pub-id><pub-id pub-id-type='pmid'>9588436</pub-id></mixed-citation></ref><ref id='B3'><mixed-citation publication-type='journal'><name><surname>Rogers</surname><given-names>S</given-names></name><name><surname>Farlow</surname><given-names>M</given-names></name><name><surname>Doody</surname><given-names>R</given-names></name><name><surname>Mohs</surname><given-names>R</given-names></name><name><surname>Friedhoff</surname><given-names>L</given-names></name><article-title>A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil study group</article-title><source>Neurology</source><year>1998</year><volume>50</volume><fpage>136</fpage><lpage>145</lpage><pub-id pub-id-type='pmid'>9443470</pub-id></mixed-citation></ref><ref id='B4'><mixed-citation publication-type='journal'><name><surname>Corey-Bloom</surname><given-names>J</given-names></name><name><surname>Anand</surname><given-names>R</given-names></name><name><surname>Veach</surname><given-names>J</given-names></name><name><surname>Group</surname><given-names>EBS</given-names></name><article-title>A randomized trial evaluating the efficacy and safety of ena 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease</article-title><source>Int J Geriatr Psychopharmacol</source><year>1998</year><volume>1</volume><fpage>55</fpage><lpage>65</lpage></mixed-citation></ref><ref id='B5'><mixed-citation publication-type='other'><name><surname>Schneider</surname><given-names>L</given-names></name><name><surname>Anand</surname><given-names>R</given-names></name><name><surname>Farlow</surname><given-names>M</given-names></name><article-title>Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease</article-title><source>Int J Geriatr Psychopharmacol</source><year>1998</year><issue>Suppl 1</issue><fpage>S26</fpage><lpage>S34</lpage></mixed-citation></ref><ref id='B6'><mixed-citation publication-type='journal'><name><surname>Rösler</surname><given-names>M</given-names></name><name><surname>Anand</surname><given-names>R</given-names></name><name><surname>Cicin-Sain</surname><given-names>A</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Agid</surname><given-names>Y</given-names></name><name><surname>Dal-Bianco</surname><given-names>P</given-names></name><name><surname>Stähelin</surname><given-names>H</given-names></name><name><surname>Hartman</surname><given-names>R</given-names></name><name><surname>Gharabawi</surname><given-names>M</given-names></name><article-title>Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial</article-title><source>BMJ</source><year>1999</year><volume>318</volume><fpage>633</fpage><lpage>638</lpage><pub-id pub-id-type='pmid'>10066203</pub-id></mixed-citation></ref><ref id='B7'><mixed-citation publication-type='journal'><name><surname>Raskind</surname><given-names>M</given-names></name><name><surname>Peskind</surname><given-names>E</given-names></name><name><surname>Wessel</surname><given-names>T</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name><article-title>Galantamine in ad: a 6-month randomized, placebo-controlled trial with a 6-month extension. The galantamine usa-1 study group</article-title><source>Neurology</source><year>2000</year><volume>54</volume><fpage>2261</fpage><lpage>2268</lpage><pub-id pub-id-type='pmid'>10881250</pub-id></mixed-citation></ref><ref id='B8'><mixed-citation publication-type='journal'><name><surname>Wilcock</surname><given-names>G</given-names></name><name><surname>Lilienfeld</surname><given-names>S</given-names></name><name><surname>Gaens</surname><given-names>E</given-names></name><article-title>Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine international-1 study group</article-title><source>BMJ</source><year>2000</year><volume>321</volume><fpage>1445</fpage><lpage>1449</lpage><pub-id pub-id-type='pmid'>11110737</pub-id><pub-id pub-id-type='doi'>10.1136/bmj.321.7274.1445</pub-id></mixed-citation></ref><ref id='B9'><mixed-citation publication-type='journal'><name><surname>Tariot</surname><given-names>P</given-names></name><name><surname>Solomon</surname><given-names>P</given-names></name><name><surname>Morris</surname><given-names>J</given-names></name><name><surname>Kershaw</surname><given-names>P</given-names></name><name><surname>Lilienfeld</surname><given-names>S</given-names></name><name><surname>Ding</surname><given-names>C</given-names></name><article-title>A 5-month, randomized, placebo-controlled trial of galantamine in ad. The galantamine usa-10 study group</article-title><source>Neurology</source><year>2000</year><volume>54</volume><fpage>2269</fpage><lpage>2276</lpage><pub-id pub-id-type='pmid'>10881251</pub-id></mixed-citation></ref><ref id='B10'><mixed-citation publication-type='journal'><name><surname>Winblad</surname><given-names>B</given-names></name><name><surname>Engedal</surname><given-names>K</given-names></name><name><surname>Soininen</surname><given-names>H</given-names></name><name><surname>Verhey</surname><given-names>F</given-names></name><name><surname>Waldemar</surname><given-names>G</given-names></name><name><surname>Wimo</surname><given-names>A</given-names></name><name><surname>Wetterholm</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Haglund</surname><given-names>A</given-names></name><name><surname>Subbiah</surname><given-names>P</given-names></name><article-title>A 1-year, randomized, placebo controlled study of donepezil in patients with mild to moderate ad</article-title><source>Neurology</source><year>2001</year><volume>57</volume><fpage>489</fpage><lpage>495</lpage><pub-id pub-id-type='pmid'>11502918</pub-id></mixed-citation></ref><ref id='B11'><mixed-citation publication-type='journal'><name><surname>Mohs</surname><given-names>R</given-names></name><name><surname>Doody</surname><given-names>R</given-names></name><name><surname>Morris</surname><given-names>J</given-names></name><name><surname>Ieni</surname><given-names>J</given-names></name><name><surname>Rogers</surname><given-names>S</given-names></name><name><surname>Perdomo</surname><given-names>C</given-names></name><name><surname>Pratt</surname><given-names>R</given-names></name><article-title>A 1-year, placebo controlled preservation of function survival study of donepezil in ad patients</article-title><source>Neurology</source><year>2001</year><volume>57</volume><fpage>481</fpage><lpage>488</lpage><pub-id pub-id-type='pmid'>11502917</pub-id></mixed-citation></ref><ref id='B12'><mixed-citation publication-type='journal'><name><surname>Black</surname><given-names>S</given-names></name><name><surname>Doody</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>McRae</surname><given-names>T</given-names></name><name><surname>Jambor</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Perdomo</surname><given-names>C</given-names></name><name><surname>Richardson</surname><given-names>S</given-names></name><article-title>Donepezil preserves cognition and global function in patients with severe Alzheimer disease</article-title><source>Neurology</source><year>2007</year><volume>69</volume><fpage>459</fpage><lpage>469</lpage><pub-id pub-id-type='doi'>10.1212/01.wnl.0000266627.96040.5a</pub-id><pub-id pub-id-type='pmid'>17664405</pub-id></mixed-citation></ref><ref id='B13'><mixed-citation publication-type='journal'><name><surname>Winblad</surname><given-names>B</given-names></name><name><surname>Kilander</surname><given-names>L</given-names></name><name><surname>Eriksson</surname><given-names>S</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Båtsman</surname><given-names>S</given-names></name><name><surname>Wetterholm</surname><given-names>A</given-names></name><name><surname>Jansson-Blixt</surname><given-names>C</given-names></name><name><surname>Haglund</surname><given-names>A</given-names></name><article-title>Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study</article-title><source>Lancet</source><year>2006</year><volume>367</volume><fpage>1057</fpage><lpage>1065</lpage><pub-id pub-id-type='doi'>10.1016/S0140-6736(06)68350-5</pub-id><pub-id pub-id-type='pmid'>16581404</pub-id></mixed-citation></ref><ref id='B14'><mixed-citation publication-type='journal'><name><surname>Feldman</surname><given-names>H</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Hecker</surname><given-names>J</given-names></name><name><surname>Vellas</surname><given-names>B</given-names></name><name><surname>Subbiah</surname><given-names>P</given-names></name><name><surname>Whalen</surname><given-names>E</given-names></name><article-title>A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease</article-title><source>Neurology</source><year>2001</year><volume>57</volume><fpage>613</fpage><lpage>620</lpage><pub-id pub-id-type='pmid'>11524468</pub-id></mixed-citation></ref><ref id='B15'><mixed-citation publication-type='journal'><name><surname>Seltzer</surname><given-names>B</given-names></name><name><surname>Zolnouni</surname><given-names>P</given-names></name><name><surname>Nunez</surname><given-names>M</given-names></name><name><surname>Goldman</surname><given-names>R</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Ieni</surname><given-names>J</given-names></name><name><surname>Richardson</surname><given-names>S</given-names></name><article-title>Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial</article-title><source>Arch Neurol</source><year>2004</year><volume>61</volume><fpage>1852</fpage><lpage>1856</lpage><pub-id pub-id-type='doi'>10.1001/archneur.61.12.1852</pub-id><pub-id pub-id-type='pmid'>15596605</pub-id></mixed-citation></ref><ref id='B16'><mixed-citation publication-type='journal'><name><surname>Courtney</surname><given-names>C</given-names></name><name><surname>Farrell</surname><given-names>D</given-names></name><name><surname>Gray</surname><given-names>R</given-names></name><name><surname>Hills</surname><given-names>R</given-names></name><name><surname>Lynch</surname><given-names>L</given-names></name><name><surname>Sellwood</surname><given-names>E</given-names></name><name><surname>Edwards</surname><given-names>S</given-names></name><name><surname>Hardyman</surname><given-names>W</given-names></name><name><surname>Raftery</surname><given-names>J</given-names></name><name><surname>Crome</surname><given-names>P</given-names></name><name><surname>Lendon</surname><given-names>C</given-names></name><name><surname>Shaw</surname><given-names>H</given-names></name><name><surname>Bentham</surname><given-names>P</given-names></name><article-title>Long-term donepezil treatment in 565 patients with Alzheimer's disease (ad2000): randomised double-blind trial</article-title><source>Lancet</source><year>2004</year><volume>363</volume><fpage>2105</fpage><lpage>2115</lpage><pub-id pub-id-type='doi'>10.1016/S0140-6736(04)16499-4</pub-id><pub-id pub-id-type='pmid'>15220031</pub-id></mixed-citation></ref><ref id='B17'><mixed-citation publication-type='other'><name><surname>Birks</surname><given-names>J</given-names></name><article-title>Cholinesterase inhibitors for Alzheimer's disease</article-title><source>Cochrane Database Syst Rev</source><year>2006</year><issue>1</issue><fpage>CD005593</fpage><pub-id pub-id-type='pmid'>16437532</pub-id></mixed-citation></ref><ref id='B18'><mixed-citation publication-type='journal'><name><surname>Winblad</surname><given-names>B</given-names></name><name><surname>Poritis</surname><given-names>N</given-names></name><article-title>Memantine in severe dementia: results of the 9 m-best study (benefit and efficacy in severely demented patients during treatment with memantine)</article-title><source>Int J Geriatr Psychiatry</source><year>1999</year><volume>14</volume><fpage>135</fpage><lpage>146</lpage><pub-id pub-id-type='doi'>10.1002/(SICI)1099-1166(199902)14:2&lt;135::AID-GPS906&gt;3.0.CO;2-0</pub-id><pub-id pub-id-type='pmid'>10885864</pub-id></mixed-citation></ref><ref id='B19'><mixed-citation publication-type='journal'><name><surname>Reisberg</surname><given-names>B</given-names></name><name><surname>Doody</surname><given-names>R</given-names></name><name><surname>Stöffler</surname><given-names>A</given-names></name><name><surname>Schmitt</surname><given-names>F</given-names></name><name><surname>Ferris</surname><given-names>S</given-names></name><name><surname>Möbius</surname><given-names>H</given-names></name><article-title>Memantine in moderate-to-severe Alzheimer's disease</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><fpage>1333</fpage><lpage>1341</lpage><pub-id pub-id-type='doi'>10.1056/NEJMoa013128</pub-id><pub-id pub-id-type='pmid'>12672860</pub-id></mixed-citation></ref><ref id='B20'><mixed-citation publication-type='journal'><name><surname>Tariot</surname><given-names>P</given-names></name><name><surname>Farlow</surname><given-names>M</given-names></name><name><surname>Grossberg</surname><given-names>G</given-names></name><name><surname>Graham</surname><given-names>S</given-names></name><name><surname>McDonald</surname><given-names>S</given-names></name><name><surname>Gergel</surname><given-names>I</given-names></name><article-title>Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial</article-title><source>JAMA</source><year>2004</year><volume>291</volume><fpage>317</fpage><lpage>324</lpage><pub-id pub-id-type='doi'>10.1001/jama.291.3.317</pub-id><pub-id pub-id-type='pmid'>14734594</pub-id></mixed-citation></ref><ref id='B21'><mixed-citation publication-type='journal'><name><surname>van Dyck</surname><given-names>C</given-names></name><name><surname>Tariot</surname><given-names>P</given-names></name><name><surname>Meyers</surname><given-names>B</given-names></name><name><surname>Malca Resnick</surname><given-names>E</given-names></name><article-title>A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease</article-title><source>Alzheimer Dis Assoc Disord</source><year>2007</year><volume>21</volume><fpage>136</fpage><lpage>143</lpage><pub-id pub-id-type='doi'>10.1097/WAD.0b013e318065c495</pub-id><pub-id pub-id-type='pmid'>17545739</pub-id></mixed-citation></ref><ref id='B22'><mixed-citation publication-type='journal'><name><surname>Cummings</surname><given-names>J</given-names></name><article-title>Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations</article-title><source>Am J Geriatr Psychiatry</source><year>2003</year><volume>11</volume><fpage>131</fpage><lpage>145</lpage><pub-id pub-id-type='pmid'>12611743</pub-id></mixed-citation></ref><ref id='B23'><mixed-citation publication-type='journal'><name><surname>Doody</surname><given-names>R</given-names></name><name><surname>Dunn</surname><given-names>J</given-names></name><name><surname>Clark</surname><given-names>C</given-names></name><name><surname>Farlow</surname><given-names>M</given-names></name><name><surname>Foster</surname><given-names>N</given-names></name><name><surname>Liao</surname><given-names>T</given-names></name><name><surname>Gonzales</surname><given-names>N</given-names></name><name><surname>Lai</surname><given-names>E</given-names></name><name><surname>Massman</surname><given-names>P</given-names></name><article-title>Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease</article-title><source>Dement Geriatr Cogn Disord</source><year>2001</year><volume>12</volume><fpage>295</fpage><lpage>300</lpage><pub-id pub-id-type='doi'>10.1159/000051272</pub-id><pub-id pub-id-type='pmid'>11351141</pub-id></mixed-citation></ref><ref id='B24'><mixed-citation publication-type='journal'><name><surname>Lopez</surname><given-names>O</given-names></name><name><surname>Becker</surname><given-names>J</given-names></name><name><surname>Wisniewski</surname><given-names>S</given-names></name><name><surname>Saxton</surname><given-names>J</given-names></name><name><surname>Kaufer</surname><given-names>D</given-names></name><name><surname>DeKosky</surname><given-names>S</given-names></name><article-title>Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2002</year><volume>72</volume><fpage>310</fpage><lpage>314</lpage><pub-id pub-id-type='pmid'>11861686</pub-id><pub-id pub-id-type='doi'>10.1136/jnnp.72.3.310</pub-id></mixed-citation></ref><ref id='B25'><mixed-citation publication-type='journal'><name><surname>Geldmacher</surname><given-names>D</given-names></name><name><surname>Provenzano</surname><given-names>G</given-names></name><name><surname>McRae</surname><given-names>T</given-names></name><name><surname>Mastey</surname><given-names>V</given-names></name><name><surname>Ieni</surname><given-names>J</given-names></name><article-title>Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease</article-title><source>J Am Geriatr Soc</source><year>2003</year><volume>51</volume><fpage>937</fpage><lpage>944</lpage><pub-id pub-id-type='doi'>10.1046/j.1365-2389.2003.51306.x</pub-id><pub-id pub-id-type='pmid'>12834513</pub-id></mixed-citation></ref><ref id='B26'><mixed-citation publication-type='journal'><name><surname>Atri</surname><given-names>A</given-names></name><name><surname>Shaughnessy</surname><given-names>L</given-names></name><name><surname>Locascio</surname><given-names>J</given-names></name><name><surname>Growdon</surname><given-names>J</given-names></name><article-title>Long-term course and effectiveness of combination therapy in Alzheimer disease</article-title><source>Alzheimer Dis Assoc Disord</source><year>2008</year><volume>22</volume><fpage>209</fpage><lpage>221</lpage><pub-id pub-id-type='pmid'>18580597</pub-id><pub-id pub-id-type='doi'>10.1097/WAD.0b013e31816653bc</pub-id></mixed-citation></ref><ref id='B27'><mixed-citation publication-type='journal'><name><surname>Lopez</surname><given-names>O</given-names></name><name><surname>Becker</surname><given-names>J</given-names></name><name><surname>Wahed</surname><given-names>A</given-names></name><name><surname>Saxton</surname><given-names>J</given-names></name><name><surname>Sweet</surname><given-names>RD</given-names></name><name><surname>Wolk</surname><given-names>D</given-names></name><name><surname>Klunk</surname><given-names>W</given-names></name><name><surname>Dekosky</surname><given-names>S</given-names></name><article-title>Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer's disease</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2009</year><volume>80</volume><fpage>600</fpage><lpage>607</lpage><pub-id pub-id-type='doi'>10.1136/jnnp.2008.158964</pub-id><pub-id pub-id-type='pmid'>19204022</pub-id></mixed-citation></ref><ref id='B28'><mixed-citation publication-type='journal'><name><surname>Karlawish</surname><given-names>J</given-names></name><name><surname>Whitehouse</surname><given-names>P</given-names></name><article-title>Is the placebo control obsolete in a world after donepezil and vitamin e?</article-title><source>Arch Neurol</source><year>1998</year><volume>55</volume><fpage>1420</fpage><lpage>1424</lpage><pub-id pub-id-type='doi'>10.1001/archneur.55.11.1420</pub-id><pub-id pub-id-type='pmid'>9823825</pub-id></mixed-citation></ref><ref id='B29'><mixed-citation publication-type='journal'><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Stadlan</surname><given-names>E</given-names></name><article-title>Clinical diagnosis of Alzheimer's disease: report of the nincds-adrda work group under the auspices of department of health and human services task force on Alzheimer's disease</article-title><source>Neurology</source><year>1984</year><volume>34</volume><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type='pmid'>6610841</pub-id></mixed-citation></ref><ref id='B30'><mixed-citation publication-type='journal'><name><surname>Doody</surname><given-names>R</given-names></name><name><surname>Pavlik</surname><given-names>V</given-names></name><name><surname>Massman</surname><given-names>P</given-names></name><name><surname>Kenan</surname><given-names>M</given-names></name><name><surname>Yeh</surname><given-names>S</given-names></name><name><surname>Powell</surname><given-names>S</given-names></name><name><surname>Cooke</surname><given-names>N</given-names></name><name><surname>Dyer</surname><given-names>C</given-names></name><name><surname>Demirovic</surname><given-names>J</given-names></name><name><surname>Waring</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>W</given-names></name><article-title>Changing patient characteristics and survival experience in an Alzheimer's center patient cohort</article-title><source>Dement Geriatr Cogn Disord</source><year>2005</year><volume>20</volume><fpage>198</fpage><lpage>208</lpage><pub-id pub-id-type='doi'>10.1159/000087300</pub-id><pub-id pub-id-type='pmid'>16088145</pub-id></mixed-citation></ref><ref id='B31'><mixed-citation publication-type='journal'><name><surname>Doody</surname><given-names>R</given-names></name><name><surname>Dunn</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>E</given-names></name><name><surname>Azher</surname><given-names>S</given-names></name><name><surname>Kataki</surname><given-names>M</given-names></name><article-title>A method for estimating duration of illness in Alzheimer's disease</article-title><source>Dement Geriatr Cogn Disord</source><year>2004</year><volume>17</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type='doi'>10.1159/000074078</pub-id><pub-id pub-id-type='pmid'>14560058</pub-id></mixed-citation></ref><ref id='B32'><mixed-citation publication-type='journal'><name><surname>Folstein</surname><given-names>M</given-names></name><name><surname>Folstein</surname><given-names>S</given-names></name><name><surname>McHugh</surname><given-names>P</given-names></name><article-title>'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician</article-title><source>J Psychiatr Res</source><year>1975</year><volume>12</volume><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type='doi'>10.1016/0022-3956(75)90026-6</pub-id><pub-id pub-id-type='pmid'>1202204</pub-id></mixed-citation></ref><ref id='B33'><mixed-citation publication-type='journal'><name><surname>Doody</surname><given-names>R</given-names></name><name><surname>Strehlow</surname><given-names>S</given-names></name><name><surname>Massman</surname><given-names>P</given-names></name><name><surname>Feher</surname><given-names>E</given-names></name><name><surname>Clark</surname><given-names>C</given-names></name><name><surname>Roy</surname><given-names>J</given-names></name><article-title>Baylor profound mental status examination: a brief staging measure for profoundly demented Alzheimer disease patients</article-title><source>Alzheimer Dis Assoc Disord</source><year>1999</year><volume>13</volume><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type='doi'>10.1097/00002093-199903000-00008</pub-id><pub-id pub-id-type='pmid'>10192643</pub-id></mixed-citation></ref><ref id='B34'><mixed-citation publication-type='journal'><name><surname>Rosen</surname><given-names>W</given-names></name><name><surname>Mohs</surname><given-names>R</given-names></name><name><surname>Davis</surname><given-names>K</given-names></name><article-title>A new rating scale for Alzheimer's disease</article-title><source>Am J Psychiatry</source><year>1984</year><volume>141</volume><fpage>1356</fpage><lpage>1364</lpage><pub-id pub-id-type='pmid'>6496779</pub-id></mixed-citation></ref><ref id='B35'><mixed-citation publication-type='journal'><name><surname>Hughes</surname><given-names>C</given-names></name><name><surname>Berg</surname><given-names>L</given-names></name><name><surname>Danziger</surname><given-names>W</given-names></name><name><surname>Coben</surname><given-names>L</given-names></name><name><surname>Martin</surname><given-names>R</given-names></name><article-title>A new clinical scale for the staging of dementia</article-title><source>Br J Psychiatry</source><year>1982</year><volume>140</volume><fpage>566</fpage><lpage>572</lpage><pub-id pub-id-type='doi'>10.1192/bjp.140.6.566</pub-id><pub-id pub-id-type='pmid'>7104545</pub-id></mixed-citation></ref><ref id='B36'><mixed-citation publication-type='journal'><name><surname>Berg</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Morris</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Rubin</surname><given-names>E</given-names></name><name><surname>Storandt</surname><given-names>M</given-names></name><name><surname>Coben</surname><given-names>L</given-names></name><article-title>Mild senile dementia of the alzheimer type: 3. Longitudinal and cross-sectional assessment</article-title><source>Ann Neurol</source><year>1990</year><volume>28</volume><fpage>648</fpage><lpage>652</lpage><pub-id pub-id-type='doi'>10.1002/ana.410280508</pub-id><pub-id pub-id-type='pmid'>2260851</pub-id></mixed-citation></ref><ref id='B37'><mixed-citation publication-type='journal'><name><surname>Morris</surname><given-names>J</given-names></name><article-title>The clinical dementia rating (cdr): Current version and scoring rules</article-title><source>Neurology</source><year>1993</year><volume>43</volume><fpage>2412</fpage><lpage>2414</lpage><pub-id pub-id-type='pmid'>8232972</pub-id></mixed-citation></ref><ref id='B38'><mixed-citation publication-type='journal'><name><surname>Lawton</surname><given-names>M</given-names></name><name><surname>Brody</surname><given-names>E</given-names></name><article-title>Assessment of older people: Self-maintaining and instrumental activities of daily living</article-title><source>Gerontologist</source><year>1969</year><volume>9</volume><fpage>179</fpage><lpage>186</lpage><pub-id pub-id-type='pmid'>5349366</pub-id></mixed-citation></ref><ref id='B39'><mixed-citation publication-type='journal'><name><surname>Doody</surname><given-names>R</given-names></name><name><surname>Massman</surname><given-names>P</given-names></name><name><surname>Dunn</surname><given-names>J</given-names></name><article-title>A method for estimating progression rates in Alzheimer disease</article-title><source>Arch Neurol</source><year>2001</year><volume>58</volume><fpage>449</fpage><lpage>454</lpage><pub-id pub-id-type='doi'>10.1001/archneur.58.3.449</pub-id><pub-id pub-id-type='pmid'>11255449</pub-id></mixed-citation></ref><ref id='B40'><mixed-citation publication-type='other'><name><surname>Doody</surname><given-names>R</given-names></name><name><surname>Pavlik</surname><given-names>V</given-names></name><name><surname>Massman</surname><given-names>P</given-names></name><name><surname>Rountree</surname><given-names>S</given-names></name><name><surname>Darby</surname><given-names>E</given-names></name><name><surname>Chan</surname><given-names>W</given-names></name><article-title>Predicting progression of Alzheimer's disease</article-title><comment> in press </comment></mixed-citation></ref><ref id='B41'><mixed-citation publication-type='journal'><name><surname>Wallin</surname><given-names>A</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>Eriksson</surname><given-names>S</given-names></name><name><surname>Båtsman</surname><given-names>S</given-names></name><name><surname>Nasman</surname><given-names>B</given-names></name><name><surname>Ekdahl</surname><given-names>A</given-names></name><name><surname>Kilander</surname><given-names>L</given-names></name><name><surname>Grut</surname><given-names>M</given-names></name><name><surname>Rydén</surname><given-names>M</given-names></name><name><surname>Wallin</surname><given-names>A</given-names></name><name><surname>Jonsson</surname><given-names>M</given-names></name><name><surname>Olofsson</surname><given-names>H</given-names></name><name><surname>Londos</surname><given-names>E</given-names></name><name><surname>Wattmo</surname><given-names>C</given-names></name><name><surname>Eriksdotter Jonhagen</surname><given-names>M</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><article-title>Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting</article-title><source>Dement Geriatr Cogn Disord</source><year>2007</year><volume>23</volume><fpage>150</fpage><lpage>160</lpage><pub-id pub-id-type='doi'>10.1159/000098052</pub-id><pub-id pub-id-type='pmid'>17312368</pub-id></mixed-citation></ref></ref-list></back></article></PAPER>